Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.96 USD
Change Today -0.07 / -1.16%
Volume 336.5K
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

corcept therapeutics inc (CORT) Snapshot

Open
$5.93
Previous Close
$6.03
Day High
$6.03
Day Low
$5.82
52 Week High
04/9/15 - $6.65
52 Week Low
05/9/14 - $1.69
Market Cap
642.0M
Average Volume 10 Days
415.0K
EPS TTM
$-0.31
Shares Outstanding
107.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORCEPT THERAPEUTICS INC (CORT)

corcept therapeutics inc (CORT) Related Bloomberg News

View More Bloomberg News

corcept therapeutics inc (CORT) Related Businessweek News

No Related Businessweek News Found

corcept therapeutics inc (CORT) Details

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

50 Employees
Last Reported Date: 03/13/15
Founded in 1998

corcept therapeutics inc (CORT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $925.9K
Chief Financial Officer and Secretary
Total Annual Compensation: $465.4K
Senior Vice President of Oncology
Total Annual Compensation: $582.6K
Chief Accounting Officer, Vice President and ...
Total Annual Compensation: $328.2K
Compensation as of Fiscal Year 2013.

corcept therapeutics inc (CORT) Key Developments

Corcept Therapeutics Incorporated Announces Executive Appointments

Corcept Therapeutics Incorporated has named John H. Johnson as chairman of the board and Richard Kollender as a director. Johnson has more than thirty years of biopharmaceutical industry experience and serves on multiple drug company boards. Kollender also sits on drug companies boards.

Corcept Therapeutics Incorporated Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for the Year 2015

Corcept Therapeutics Incorporated reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenues of $9,013,000 compared to $4,115,000 a year ago. Loss from operations was $3,077,000 compared to $10,029,000 a year ago. Net loss was $3,895,000 or $0.04 per basic and diluted share compared to $11,124,000 or $0.11 per basic and diluted share a year ago. Non-GAAP net loss was $1,706,000 or $0.02 per basic and diluted share compared to $8,741,000 or $0.09 per basic and diluted share a year ago. For the year, the company reported revenues of $26,551,000 compared to $10,357,000 a year ago. Loss from operations was $27,619,000 compared to $41,496,000 a year ago. Net loss was $31,383,000 or $0.31 per basic and diluted share compared to $46,011,000 or $0.46 per basic and diluted share a year ago. Non-GAAP net loss was $22,504,000 or $0.22 per basic and diluted share compared to $36,405,000 or $0.36 per basic and diluted share a year ago. The company estimates 2015 net revenue will be between $47 million and $53 million.

Corcept Therapeutics Incorporated Announces Sales Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for the Year 2015; Provides Clinical Update

Corcept Therapeutics Incorporated announced sales results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported estimated net revenue of $9.0 million, a 24% increase from the prior quarter and a 119% increase from the same period last year. For the full year, the company reported estimated net revenue of $26.6 million, exceeds 2013 results by 156%. The company estimates 2015 net revenue to be between $47 million and $53 million. The company provided clinical update. It has completed the dose-finding portion of its Phase 1/2 trial of Korlym in combination with eribulin for the treatment of glucocorticoid receptor-positive (GR-positive) TNBC. Recruitment of 20 patients to participate in the trial's efficacy phase is underway. These patients will receive 300 mg of Korlym daily, with eribulin at a dose of 1.1 mg/m2 administered intravenously. Results are expected in 2015. Although the dose-finding phase of the study was designed to assess only safety and tolerability, some preliminary efficacy data are available. Of the six patients in that phase who received the selected dose, three have TNBC. The only patient known to have GR-positive TNBC exhibited a partial response, defined as a 30% or greater reduction in tumor size, and has been on therapy for nine cycles. In contrast, the only patient known to have GR-negative TNBC suffered progression of disease. The trial builds on pre-clinical and clinical research performed by investigators at the University of Chicago and at Corcept showing that Korlym's competitive blockade of GR inhibits TNBC tumor cells from escaping chemotherapy. Corcept has developed a proprietary CLIA-validated diagnostic test for identifying GR-positive tumors. All patients that enroll in the trial's efficacy phase will have GR-positive TNBC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORT:US $5.96 USD -0.07

CORT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Novartis AG SFr.97.20 CHF -1.85
View Industry Companies
 

Industry Analysis

CORT

Industry Average

Valuation CORT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORCEPT THERAPEUTICS INC, please visit www.corcept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.